TherapeuticsMD to Present Data from Phase 3 Rejoice Trial at Upcoming Investor & Medical Conferences

BOCA RATON, Fla.–(BUSINESS WIRE)–TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare
company, today announced that the company will present detailed results
from the phase 3 Rejoice Trial for its TX-004HR product candidate at
separate upcoming investor and medical conferences. TX-004HR is an
applicator-free vaginal estradiol softgel drug candidate for the
treatment of moderate to severe vaginal pain during sexual intercourse
(dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to

Details for the presentations include:

  • Company executives and medical experts will review the detailed phase
    3 data during a presentation on March 7 at the Cowen and Company 36th
    Annual Health Care Conference at the Boston Marriott Copley Place. The
    presentation will take place at 4:40 p.m. ET and will be webcast live
    at the following link:
    The webcast can also be accessed from the company’s website,,
    in the “Investors & Media” section. Following the conference, the
    webcast replay will be available on the company’s website for at least
    30 days.
  • The phase 3 data will also be summarized during two poster
    presentations at ENDO 2016, the annual meeting of the Endocrine
    Society, in Boston, April 1-4. Abstracts for both posters, “Vaginal
    Estradiol Effectively Treats Vulvar and Vaginal Atrophy (VVA) with
    Negligible to Low Systemic Absorption of Estradiol” and “The Rejoice
    Trial: A Phase 3 Randomized Controlled Trial Evaluating the Safety and
    Efficacy of a Novel Vaginal Estradiol Softgel Capsule for Symptomatic
    Vulvar and Vaginal Atrophy (VVA)” will be published online by the
    Endocrine Society on or about March 8.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on
developing and commercializing products exclusively for women. With its
SYMBODA™ technology, TherapeuticsMD is developing advanced hormone
therapy pharmaceutical products to enable delivery of bio-identical
hormones through a variety of dosage forms and administration routes.
The company’s clinical development pipeline includes two phase 3
products. The company also manufactures and distributes branded and
generic prescription prenatal vitamins as well as over-the-counter
vitamins under the vitaMedMD® and BocaGreenMD®

Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include, but
are not limited to, statements relating to TherapeuticsMD’s objectives,
plans and strategies as well as statements, other than historical facts,
that address activities, events or developments that the company
intends, expects, projects, believes or anticipates will or may occur in
the future. These statements are often characterized by terminology such
as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,”
“plans,” “will,” “expects,” “estimates,” “projects,” “positioned,”
“strategy” and similar expressions and are based on assumptions and
assessments made in light of management’s experience and perception of
historical trends, current conditions, expected future developments and
other factors believed to be appropriate. Forward-looking statements in
this press release are made as of the date of this press release, and
the company undertakes no duty to update or revise any such statements,
whether as a result of new information, future events or otherwise.
Forward-looking statements are not guarantees of future performance and
are subject to risks and uncertainties, many of which are outside of the
company’s control. Important factors that could cause actual results,
developments and business decisions to differ materially from
forward-looking statements are described in the sections titled “Risk
Factors” in the company’s filings with the Securities and Exchange
Commission, including its most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and
include the following: the company’s ability to maintain or increase
sales of its products; the company’s ability to develop and
commercialize its hormone therapy drug candidates and obtain additional
financing necessary therefor; the length, cost and uncertain results of
the company’s clinical trials; the potential of adverse side effects or
other safety risks that could preclude the approval of the company’s
hormone therapy drug candidates; the company’s reliance on third parties
to conduct its clinical trials, research and development and
manufacturing; the availability of reimbursement from government
authorities and health insurance companies for the company’s products;
the impact of product liability lawsuits; the influence of extensive and
costly government regulation; the volatility of the trading price of the
company’s common stock and the concentration of power in its stock
ownership. PDF copies of the company’s historical press releases and
financial tables can be viewed and downloaded at its website:


TherapeuticsMD, Inc.
Cartwright, 561-961-1900
Chief Financial Officer
Fox, 212-257-6724
Director, Media & Engagement